Home|Journals|Articles by Year Follow on Twitter| Subscribe to List

Directory for Medical Articles

Open Access

Case Report

Ann Med Res. 2015; 22(4): 269-271

Dramatic Response to Systemic Bevacizumab Therapy in a Patient with Hereditary Hemorrhagic Telangiectasia

Mehmet Hilmi Dogu, Ismail Sari, Sibel Hacioglu, Sema Selcuk, Ali Keskin.

Hereditary hemorrhagic telangiectasia is a rare multisystem vascular disorder. Also known as Rendu Osler syndrome, it is characterized by mucocutaneous telangiectases, epistaxis, gastrointestinal bleeding, and visceral arteriovenous malformations.
A sixty-two-year old male patient was followed due to hereditary hemorrhagic telangiectasia. Because of high transfusion dependency he received bevacizumab administration at a dose of 5 mg/kg every 2 weeks, for a total of eight cycles. We achieved considerable response in terms of the dependency of transfusion after bevacizumab treatment. Serum and tissue expression of vascular endothelial growth factor is increased in patients with hereditary hemorrhagic telangiectasia. Thus, logically, vascular endothelial growth factor inhibitors could be expected to function in the therapy of hereditary hemorrhagic telangiectasia as well.

Key words: Hereditary Hemorrhagic Telangiectasia; Bleeding; Bevacizumab.

Full-text options

Full-text Article

Journal of Interdisciplinary Histopathology


BiblioMed Home
Follow ScopeMed on Twitter
Author Tools
eJPort Journal Hosting
About BiblioMed
License Information
Terms & Conditions
Privacy Policy
Contact Us

The articles in Bibliomed are open access articles licensed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License (https://creativecommons.org/licenses/by-nc-sa/4.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.
ScopeMed is a Database Service for Scientific Publications. Copyright ScopeMed Information Services.